SE509694C2 - Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter - Google Patents

Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter

Info

Publication number
SE509694C2
SE509694C2 SE9102604A SE9102604A SE509694C2 SE 509694 C2 SE509694 C2 SE 509694C2 SE 9102604 A SE9102604 A SE 9102604A SE 9102604 A SE9102604 A SE 9102604A SE 509694 C2 SE509694 C2 SE 509694C2
Authority
SE
Sweden
Prior art keywords
composition according
methyl
bismuth
ranitidine
salt
Prior art date
Application number
SE9102604A
Other languages
English (en)
Swedish (sv)
Other versions
SE9102604D0 (sv
SE9102604L (sv
Inventor
Norman Richard Smith
Colin Roy Heppenstall
Stephen John Douglas
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SE9102604D0 publication Critical patent/SE9102604D0/xx
Publication of SE9102604L publication Critical patent/SE9102604L/xx
Publication of SE509694C2 publication Critical patent/SE509694C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
SE9102604A 1990-09-11 1991-09-10 Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter SE509694C2 (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909019875A GB9019875D0 (en) 1990-09-11 1990-09-11 Pharmaceutical compositions
NO920408A NO179694C (no) 1990-09-11 1992-01-30 Farmasöytiske preparater inneholdende ranitidinderivater
PCT/EP1992/000498 WO1993017679A1 (en) 1990-09-11 1992-03-05 Compositions containing ranitidine/bismuth carboxylates salts

Publications (3)

Publication Number Publication Date
SE9102604D0 SE9102604D0 (sv) 1991-09-10
SE9102604L SE9102604L (sv) 1992-03-12
SE509694C2 true SE509694C2 (sv) 1999-02-22

Family

ID=47884627

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9102604A SE509694C2 (sv) 1990-09-11 1991-09-10 Farmaceutiska kompositioner innehållande ranitidin/vismut karboxylsyra salter

Country Status (33)

Country Link
US (1) US5456925A (de)
EP (1) EP0558779B1 (de)
JP (1) JPH0692849A (de)
KR (1) KR100196308B1 (de)
AT (2) AT405134B (de)
AU (2) AU640816B2 (de)
BE (1) BE1005115A5 (de)
BG (1) BG61931B1 (de)
CA (1) CA2050970C (de)
CH (1) CH683068A5 (de)
CY (1) CY1988A (de)
DE (2) DE4130061A1 (de)
DK (1) DK159191A (de)
ES (1) ES2072647T3 (de)
FI (1) FI944047A0 (de)
FR (1) FR2666508B1 (de)
GB (2) GB9019875D0 (de)
HK (1) HK60894A (de)
HU (1) HU211846A9 (de)
IE (1) IE65049B1 (de)
IL (1) IL99428A (de)
IT (1) IT1249696B (de)
MX (1) MX9101009A (de)
NL (1) NL194907C (de)
NO (1) NO179694C (de)
NZ (1) NZ239731A (de)
OA (1) OA10093A (de)
RO (1) RO112084B1 (de)
RU (1) RU2108097C1 (de)
SE (1) SE509694C2 (de)
SK (1) SK279591B6 (de)
WO (1) WO1993017679A1 (de)
ZA (1) ZA917176B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
GB9120131D0 (en) * 1991-09-20 1991-11-06 Glaxo Group Ltd Medicaments
DK0550083T3 (da) * 1991-12-06 1999-10-11 Glaxo Group Ltd Lægemidler til behandling af inflammatoriske tilstande eller til analgesi og indeholdende et NSAID og ranitidinbismuthcitra
GB9127150D0 (en) * 1991-12-20 1992-02-19 Smithkline Beecham Plc Novel treatment
GB9501560D0 (en) 1995-01-26 1995-03-15 Nycomed Imaging As Contrast agents
JPH10512877A (ja) * 1995-01-26 1998-12-08 ニコムド イメージング エイ／エス ビスマス化合物
RU2203048C2 (ru) * 1998-08-18 2003-04-27 Леонидов Николай Борисович Физически устойчивая рентгеноаморфная форма ранитидина гидрохлорида с повышенной противоязвенной активностью и способ ее получения
EP1104673A1 (de) * 1999-11-30 2001-06-06 Bayer Classics Ein Hydrogencarbonat enthaltendes sprengmittelfreies Arzneimittel
KR100412290B1 (ko) * 2001-11-27 2003-12-31 주식회사 동구제약 라니티딘 함유 현탁제 조성물 및 그의 제조방법
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
US9629809B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
MX337488B (es) * 2008-07-21 2016-03-08 Si Group Inc Granulos con alto contenido de ibuprofeno sodico, su preparacion y su uso en preparar formas de dosificacion solidas no efervescentes.
US20230218663A1 (en) * 2020-06-01 2023-07-13 The University Of Hong Kong Compositions and methods for treating a sars-cov-2 infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608257A (en) * 1984-01-03 1986-08-26 Board Of Regents For Oklahoma State University Composition and method for treating heat stress
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
EP0282132B1 (de) * 1987-03-09 1992-09-30 The Procter & Gamble Company Zusammensetzungen und ihre Verwendung zur Behandlung von Magen-Darmstörungen
DE3710462A1 (de) * 1987-03-30 1988-10-13 Heumann Pharma Gmbh & Co Pharmazeutische zubereitung zur behandlung von erkrankungen des magen-darm-traktes
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
CH679582A5 (de) * 1988-07-18 1992-03-13 Glaxo Group Ltd
EP0363502B1 (de) * 1988-10-08 1991-09-25 Dr. R. Pfleger Chemische Fabrik Gmbh Flüssiges, wismuthaltiges Arzneipräparat, Verfahren zum Herstellen desselben und seine Verwendung
AU641903B2 (en) * 1988-10-26 1993-10-07 Glaxo Group Limited Carboxylic acid derivatives
US5013560A (en) * 1989-03-17 1991-05-07 The Procter & Gamble Company Microbially-stable bismuth-containing liquid pharmaceutical suspensions
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
EP0558779A1 (de) 1993-09-08
FR2666508B1 (fr) 1994-02-18
IE65049B1 (en) 1995-10-04
IL99428A0 (en) 1992-08-18
GB9019875D0 (en) 1990-10-24
KR920005984A (ko) 1992-04-27
NZ239731A (en) 1993-10-26
NO920408D0 (no) 1992-01-30
FR2666508A1 (fr) 1992-03-13
ATE122883T1 (de) 1995-06-15
BE1005115A5 (fr) 1993-04-27
BG99021A (bg) 1995-06-30
DK159191D0 (da) 1991-09-10
CY1988A (en) 1997-09-05
SE9102604D0 (sv) 1991-09-10
BG61931B1 (bg) 1998-10-30
IL99428A (en) 1996-06-18
GB2248185A (en) 1992-04-01
SK106094A3 (en) 1995-02-08
ES2072647T3 (es) 1995-07-16
US5456925A (en) 1995-10-10
CA2050970C (en) 2002-11-19
ZA917176B (en) 1992-06-24
RU2108097C1 (ru) 1998-04-10
AT405134B (de) 1999-05-25
AU640816B2 (en) 1993-09-02
CH683068A5 (fr) 1994-01-14
RO112084B1 (ro) 1997-05-30
SK279591B6 (sk) 1999-01-11
FI944047L (fi) 1994-09-02
ATA180191A (de) 1998-10-15
NL9101533A (nl) 1992-04-01
NO179694B (no) 1996-08-26
ITRM910673A1 (it) 1993-03-10
GB9119284D0 (en) 1991-10-23
AU8375791A (en) 1992-03-19
FI944047A7 (fi) 1994-09-02
DK159191A (da) 1992-03-12
JPH0692849A (ja) 1994-04-05
NL194907B (nl) 2003-03-03
SE9102604L (sv) 1992-03-12
NO179694C (no) 1996-12-04
HU211846A9 (en) 1995-12-28
DE4130061A1 (de) 1992-03-12
HK60894A (en) 1994-07-08
KR100196308B1 (ko) 1999-06-15
IT1249696B (it) 1995-03-09
EP0558779B1 (de) 1995-05-24
GB2248185B (en) 1994-02-02
ITRM910673A0 (it) 1991-09-10
AU1334792A (en) 1993-10-05
IE913191A1 (en) 1992-04-22
FI944047A0 (fi) 1994-09-02
MX9101009A (es) 1992-05-04
WO1993017679A1 (en) 1993-09-16
CA2050970A1 (en) 1992-03-12
NL194907C (nl) 2003-07-04
NO920408L (no) 1993-08-02
DE69202696D1 (de) 1995-06-29
OA10093A (en) 1996-12-18

Similar Documents

Publication Publication Date Title
RU2142790C1 (ru) Фармацевтическая композиция, стабилизированная основным агентом
WO1999053918A1 (en) Stabilized compositions containing benzimidazole-type compounds
US4370313A (en) Nitrofurantoin dosage form
KR100196308B1 (ko) 푸란 유도체를 함유하는 제약 조성물
CA2361843C (en) Swallowable tablets with high content of n-acetylcysteine
US3865935A (en) Tableting of erythromycin base
RU2197244C2 (ru) Фармацевтическая композиция и фармацевтический препарат, содержащие калиевую, натриевую и трис соли оксапрозина, их применение для устранения или уменьшения боли у млекопитающего и для лечения воспаления и нарушений, связанных с воспалением у млекопитающего, способ получения фармацевтического препарата
US3891755A (en) Dosage formulation for erythromycin cetyl sulfate
EP2117534B1 (de) Pharmazeutische zusammensetzung mit atorvastatin als wirkstoff
JP4902928B2 (ja) 製剤の安定化方法
US5091191A (en) Pharmaceutical composition with improved dissolution property
JPH05262649A (ja) 医薬組成物
JPH1121236A (ja) ロキソプロフェン・ナトリウム固形製剤
JPWO2001089573A1 (ja) 製剤の安定化方法
US3993778A (en) Anti-ulcerogenic pharmaceutical compositions containing a 2-amino-3,5-dibromo-benzylamine and method of use
HU217587B (hu) Ranitidint és bizmut-karboxilát-komplexet, valamint bázisos sókat tartalmazó gyógyászati készítmények
CZ209794A3 (en) Pharmaceutical preparation

Legal Events

Date Code Title Description
NUG Patent has lapsed